GSK · Pharma and healthcare · one day
GSK (GSK): news on Saturday 24 October 2026
News from the 24 hours to Saturday morning, 24 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mainly positive, led by FDA approvals including a hepatitis B treatment and new cancer drug licensing rights from HUTCHMED. Some share price pieces noted a small fall and margin pressure, but these were minor against the pipeline news.
What drove it
- FDA approvals
- cancer drug licensing deal
- share price margin pressure
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sun 18 Oct | +0.7 | 2 |
| Mon 19 Oct | +8.5 | 7 |
| Tue 20 Oct | +8.3 | 37 |
| Wed 21 Oct | +10.0 | 26 |
| Thu 22 Oct | +10.0 | 37 |
| Fri 23 Oct | +7.2 | 18 |
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
8 stories · 15 headlines · strongest first
Pharma and healthcare on 24 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| FDA clears Hibsago, GSK's medicine for chronic hepatitis B +10.04 headlines today · 45 in all, since 21 October · Reports cover FDA approval of Hibsago, including two approvals in a week. | ||
| +10.0 | FDA approval of hepatitis B treatment is a major win. | |
| +10.0 | Double FDA win highlighted. | |
| +10.0 | FDA granted GSK two approvals within a single week. | |
| +8.3 | Approval win and Jefferies analyst backing. | |
| HUTCHMED licensing deal with GSK closes +5.83 headlines today · 12 in all, since 15 October · Reports say GSK secured ex-China rights to a KRAS EGFR cancer drug from HUTCHMED. | ||
| +7.5 | Secures exclusive rights to first-in-class cancer therapy; pipeline boost. | |
| +7.5 | Obtains rights outside China to a cancer drug targeting KRAS and EGFR. | |
| +5.0 | Licensing deal for HUTCHMED drug benefits GSK pipeline. | |
| GSK share price moves and technical views −4.62 headlines today · Traders Union says GSK fell around 1.5% amid technical signals. | ||
| −5.0 | Share fall on net margin profit pressure. | |
| −4.2 | Concern about deeper losses on overbought signals. | |
| GSK third-quarter results due 28 October +0.22 headlines today · GSK results are scheduled for 28 October and listed in week-ahead previews. | ||
| +0.3 | Factual announcement of third-quarter results date. | |
| 0.0 | Preview of upcoming results; neutral. | |
| Lung cancer trial records 61% response rate for GSK's Ris-Rez +7.51 headline today · 15 in all, since 19 October · At ESMO, GSK's head of cancer research and development said mo-rez results strengthen its conviction in ADCs. | ||
| +6.7 | GSK cancer research head confident in ADC data as phase 3 work grows. | |
| GSK on UAE digital health investments +2.51 headline today · GSK comments on UAE digital health investments. | ||
| +2.5 | GSK comments on UAE digital health opportunities. | |
| Pharma news roundup mentioning GSK +1.71 headline today · Rx Rundown includes GSK. | ||
| +1.7 | Roundup mentioning GSK deal with Hansoh; mildly positive. | |
| GSK's Deborah Waterhouse picked to lead CSL as chief executive −3.31 headline today · 6 in all, since 22 October · Fierce Biotech reports CSL enlisting Deborah Waterhouse. | ||
| +1.7 | Former GSK executive appointed CSL chief; minor reputational note. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.